IA Trial Radar | ||
|---|---|---|
O estudo clínico NCT07315958 (ALSAC) para Respiratory (Chronic Obstructive Pulmonary Disease) está em recrutamento. Consulte a visualização em cartões do Radar de Estudos Clínicos e as ferramentas de descoberta de IA para ver todos os detalhes. Ou pergunte qualquer coisa aqui. | ||
Um estudo corresponde aos critérios do filtro
Visualização em cartões
Voltar à pesquisa
AstraZenecaStudy for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics (ALSAC) 1.000 Observacional Design adaptativo
Os detalhes do estudo clínico estão disponíveis principalmente em inglês. No entanto, a IA Trial Radar pode ajudar! Basta clicar em 'Explicar o estudo' para visualizar e discutir as informações do estudo no idioma selecionado.
O estudo clínico NCT07315958 (ALSAC) é um estudo observacional para Respiratory (Chronic Obstructive Pulmonary Disease). Seu status atual é: em recrutamento. O estudo começou em 19 de dezembro de 2025 e pretende incluir 1.000 participantes. Coordenado por AstraZeneca e deve ser concluído em 30 de setembro de 2026. Essas informações foram atualizadas no ClinicalTrials.gov em 30 de março de 2026.
Resumo
Chronic Obstructive Pulmonary Disease (COPD) is a global health concern, associated with structural lung abnormalities causing persistent airflow limitation (AL) and often result from cigarette smoking. In Turkey, COPD was ranked the third among the mortality causes and the eighth among disability causes, with 9.1% to 19.1% prevalence rate. In the Middle East and North Africa (MENA) region, an increase of 30.6% in ag...Mostrar mais
Título oficial
A Multinational, Multicenter, Observational, Prospective Cohort Study for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics
Condições médicas
Respiratory (Chronic Obstructive Pulmonary Disease)Outros IDs do estudo
- ALSAC
- D5980R00124
Número NCT
Data de início (real)
2025-12-19
Última atualização postada
2026-03-30
Data de conclusão (estimada)
2026-09-30
Inscrição (estimada)
1.000
Tipo de estudo
Observacional
Status
Em recrutamento
Palavras-chave
chronic obstructive pulmonary disease
Desfecho primário
Desfecho secundário
| Medida de desfecho | Descrição da medida | Prazo |
|---|---|---|
Prevalence (number and percentage) of outpatients attending cardiology clinics, with a history of smoking who exhibit concurrent AL consistent with COPD. | Prevalence (number and percentage) of outpatients attending cardiology clinics, with a history of smoking who exhibit concurrent AL consistent with COPD. | 1 Year |
| Medida de desfecho | Descrição da medida | Prazo |
|---|---|---|
The proportion of patients with CVD who were previously diagnosed with COPD. | The proportion of patients with CVD who were previously diagnosed with COPD. | 1 Year |
The distribution of patients with AL consistent with COPD among AL severity GOLD grades 1-4. | The distribution of patients with AL consistent with COPD among AL severity GOLD grades 1-4.
GOLD 1 = MILD GOLD 2 = Moderate GOLD 3 = Severe GOLD 4 = Very Severe | 1 Year |
CAAT score of patients with AL consistent with COPD. | CAAT score of patients with AL consistent with COPD. 10-20: Medium impact on daily life. 20-30: High impact. \>30: Very high impact. | 1 Year |
The severity of COPD | The severity of COPD using GOLD ABE assessment scheme.
Group A: Low Risk, Low Symptoms Group B: Low Risk, High Symptoms Group E: High Risk | 1 year |
Assistente de participação
Critérios de elegibilidade
Idades elegíveis
Criança, Adulto, Idoso
Sexos elegíveis
Todos
- Patients aged 40 years or older.
- Patients with a smoking history of 10 pack-years or more.
- Patients willing and able to complete pulmonary function test, using a spirometer.
- Patients who have provided written consent to participate in the study.
- Patients attending cardiology clinics at the participating centers.
- Patients willing and able to complete the CAAT questionnaire.
A. Patients diagnosed with bronchial asthma. B. Patients who used a bronchodilator for an acute respiratory infection before performing spirometry.
AstraZenecaContato central do estudo
Contato: AstraZeneca Clinical Study Information Center, 1-877-240-9479, [email protected]
2 Locais do estudo em 1 países
Research Site, Ankara, Turkey (Türkiye)
Em recrutamento
Research Site, Istanbul, Turkey (Türkiye)
Em recrutamento